TH-Z835

Cat. No.:	HY-146243
CAS No.:	2766209-50-9
Molecular Formula:	$C_{30}H_{38}N_6O$
Molecular Weight:	498.66
Target:	Ras; Apoptosis
Pathway:	GPCR/G Protein; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	TH-Z835 is a mutant selective KRAS (G12D) inhibitor with an IC_{50} of 1.6 μM. TH-Z835 inhibits both mantGMPPNP/GPPNP exchange and GPPNP/mantGMPPNP exchange[1].
IC_{50} & Target	KRAS(G12D) 1.6 μM (IC_{50})
In Vitro	TH-Z835 reduces the pERK level in PANC-1 cells with an IC_{50} value less than 2.5 μM[1]. TH-Z835 conferres anti-proliferative effects, reduces the pERK and pAKT levels and induces apoptosis in other non-G12D mutant cancer cell lines, including 4T1 (KRAS(WT)), MIA PaCa-2 (KRAS(G12C)), CFPAC-1 (KRAS(G12V)), and HCT116 (KRAS(G13D)) cells, suggesting off-target effects[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	TH-Z835 (10 mg/kg; ip) reduces the tumor volumes in the C57BL/6 mice model. TH-Z835 induces apoptosis and inhibits MAPK signaling in vivo[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Mao Z, et al. KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge. Cell Discov. 2022 Jan 25;8(1):5.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA